Your browser doesn't support javascript.
Human NLRP1 is a sensor of pathogenic coronavirus 3CL proteases in lung epithelial cells.
Planès, Rémi; Pinilla, Miriam; Santoni, Karin; Hessel, Audrey; Passemar, Charlotte; Lay, Kenneth; Paillette, Perrine; Valadão, Ana-Luiza Chaves; Robinson, Kim Samirah; Bastard, Paul; Lam, Nathaniel; Fadrique, Ricardo; Rossi, Ida; Pericat, David; Bagayoko, Salimata; Leon-Icaza, Stephen Adonai; Rombouts, Yoann; Perouzel, Eric; Tiraby, Michèle; Zhang, Qian; Cicuta, Pietro; Jouanguy, Emmanuelle; Neyrolles, Olivier; Bryant, Clare E; Floto, Andres R; Goujon, Caroline; Lei, Franklin Zhong; Martin-Blondel, Guillaume; Silva, Stein; Casanova, Jean-Laurent; Cougoule, Céline; Reversade, Bruno; Marcoux, Julien; Ravet, Emmanuel; Meunier, Etienne.
  • Planès R; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France; InvivoGen, Toulouse, France; IRIM, University of Montpellier, CNRS, Montpellier, France. Electronic address: remi.planes@ipbs.fr.
  • Pinilla M; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France; InvivoGen, Toulouse, France.
  • Santoni K; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Hessel A; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Passemar C; Molecular Immunity Unit, University of Cambridge Department of Medicine, MRC-Laboratory of Molecular Biology, Cambridge, UK.
  • Lay K; Institute of Medical Biology, Agency of Science, Technology and Research, 8A Biomedical Grove, #06-06 Immunos, 138648 Singapore, Singapore; Laboratory of Human Genetics and Therapeutics, Genome Institute of Singapore (GIS), A(∗)STAR, Singapore, Singapore.
  • Paillette P; InvivoGen, Toulouse, France.
  • Valadão AC; IRIM, University of Montpellier, CNRS, Montpellier, France.
  • Robinson KS; A(∗)STAR Skin Research Laboratories, 11 Mandalay Road, 308232 Singapore, Singapore.
  • Bastard P; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases,
  • Lam N; University of Cambridge, Department of Veterinary Medicine, Cambridge CB30ES, UK; University of Cambridge, School of Clinical Medicine, Box 111, Cambridge Biomedical Campus, Cambridge CB2 0SP, UK.
  • Fadrique R; Biological and Soft Systems, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, UK.
  • Rossi I; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Pericat D; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Bagayoko S; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Leon-Icaza SA; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Rombouts Y; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Perouzel E; InvivoGen, Toulouse, France.
  • Tiraby M; InvivoGen, Toulouse, France.
  • Zhang Q; University of Paris, Imagine Institute, Paris, France.
  • Cicuta P; Biological and Soft Systems, Cavendish Laboratory, University of Cambridge, JJ Thomson Avenue, Cambridge CB3 0HE, UK.
  • Jouanguy E; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases,
  • Neyrolles O; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Bryant CE; University of Cambridge, Department of Veterinary Medicine, Cambridge CB30ES, UK; University of Cambridge, School of Clinical Medicine, Box 111, Cambridge Biomedical Campus, Cambridge CB2 0SP, UK.
  • Floto AR; Molecular Immunity Unit, University of Cambridge Department of Medicine, MRC-Laboratory of Molecular Biology, Cambridge, UK.
  • Goujon C; IRIM, University of Montpellier, CNRS, Montpellier, France.
  • Lei FZ; A(∗)STAR Skin Research Laboratories, 11 Mandalay Road, 308232 Singapore, Singapore; Lee Kong Chian School of Medicine, Nanyang Technological University, 11 Mandalay Road, 308232 Singapore, Singapore; Skin Research Institute of Singapore (SRIS), 11 Mandalay Road, 308232 Singapore, Singapore.
  • Martin-Blondel G; Service des Maladies Infectieuses et Tropicales, CHU de Toulouse, Toulouse, France; Institut Toulousain des Maladies Infectieuses et Inflammatoires (Infinity), INSERM UMR1291 - CNRS UMR5051 - Université Toulouse III, Toulouse, France.
  • Silva S; Critical Care Unit, University Hospital of Purpan, Toulouse, France.
  • Casanova JL; Laboratory of Human Genetics of Infectious Diseases, Necker Branch, Institut National de la Santé et de la Recherche Médicale U1163, Necker Hospital for Sick Children, Paris, France; University of Paris, Imagine Institute, Paris, France; St. Giles Laboratory of Human Genetics of Infectious Diseases,
  • Cougoule C; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Reversade B; Institute of Medical Biology, Agency of Science, Technology and Research, 8A Biomedical Grove, #06-06 Immunos, 138648 Singapore, Singapore; Laboratory of Human Genetics and Therapeutics, Genome Institute of Singapore (GIS), A(∗)STAR, Singapore, Singapore; Institute of Molecular and Cell Biolog
  • Marcoux J; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France.
  • Ravet E; InvivoGen, Toulouse, France.
  • Meunier E; Institute of Pharmacology and Structural Biology (IPBS), University of Toulouse, CNRS, Toulouse, France. Electronic address: etienne.meunier@ipbs.fr.
Mol Cell ; 82(13): 2385-2400.e9, 2022 07 07.
Article in English | MEDLINE | ID: covidwho-1851815
ABSTRACT
Inflammation observed in SARS-CoV-2-infected patients suggests that inflammasomes, proinflammatory intracellular complexes, regulate various steps of infection. Lung epithelial cells express inflammasome-forming sensors and constitute the primary entry door of SARS-CoV-2. Here, we describe that the NLRP1 inflammasome detects SARS-CoV-2 infection in human lung epithelial cells. Specifically, human NLRP1 is cleaved at the Q333 site by multiple coronavirus 3CL proteases, which triggers inflammasome assembly and cell death and limits the production of infectious viral particles. Analysis of NLRP1-associated pathways unveils that 3CL proteases also inactivate the pyroptosis executioner Gasdermin D (GSDMD). Subsequently, caspase-3 and GSDME promote alternative cell pyroptosis. Finally, analysis of pyroptosis markers in plasma from COVID-19 patients with characterized severe pneumonia due to autoantibodies against, or inborn errors of, type I interferons (IFNs) highlights GSDME/caspase-3 as potential markers of disease severity. Overall, our findings identify NLRP1 as a sensor of SARS-CoV-2 infection in lung epithelia.
Subject(s)
Keywords

Full text: Available Collection: International databases Database: MEDLINE Main subject: Epithelial Cells / Inflammasomes / NLR Proteins / Coronavirus 3C Proteases / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Mol Cell Journal subject: Molecular Biology Year: 2022 Document Type: Article

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: Epithelial Cells / Inflammasomes / NLR Proteins / Coronavirus 3C Proteases / SARS-CoV-2 / COVID-19 Type of study: Prognostic study Limits: Humans Language: English Journal: Mol Cell Journal subject: Molecular Biology Year: 2022 Document Type: Article